



13 April 2004

The Manager
 Company Announcements
 Australian Stock Exchange
 4th Floor
 20 Bridge Street
 SYDNEY NSW 2000

Dear Sir,

TGA SUBMISSION FOR FERRISCAN LODGED

Resonance Health is pleased to announce that its subsidiary company, Inner Vision Biometrics Pty Ltd, ("IVB") has lodged its submission to the Australian Therapeutic Goods Administration (TGA) for approval to market FerriScan.

FerriScan is a novel non invasive liver diagnosis technology designed to replace liver needle biopsies for the measurement of iron overload in the liver and with potentially broader application in other areas of liver disease such as fibrosis caused by hepatitis.

Under recently concluded reciprocal registration arrangements with European authorities, should FerriScan be included on the Australian Register of Therapeutic Goods (ARTG), immediate reciprocal registration in Europe can be obtained. The material assembled for the TGA submission in Australia will also form the basis for a U.S. FDA regulatory approval application for FerriScan planned for the second half of 2004.

Further information concerning Resonance Health and FerriScan can be obtained from our web sites at: www.resonancehealth.com www.ferriscan.com

Yours truly,

Tony Fitzgerald
Managing Director

For further information:	
Media / investor relations	Company
Rebecca Christie, Buchan (02) 9293 2836 0417 382 391 rchristie@bcg.com.au	Mr Tony Fitzgerald, Managing Director Resonance Health Limited (08) 9389 5933 0418 903 647 tfitzgerald@resonancehealth.com